Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7806911 | 1.00 | PTGS1 (0.62) | PTGS1PTGS2MT-CO2ADRB1ADRA1A | |
| SCHEMBL7807735 | 0.84 | KMT2A (0.55) | PTGS1PTGS2ADRB1ADRA1AMIF | |
| SCHEMBL31074078 | 0.83 | ADRB1 (0.45) | PTGS1PTGS2ADRB1ADRA1AMIF | |
| SCHEMBL24260675 | 0.83 | ADRB1 (0.45) | PTGS1PTGS2ADRB1ADRA1AMIF | |
| SCHEMBL3905021 | 0.83 | ADRB1 (0.45) | PTGS1PTGS2ADRB1ADRA1AMIF | |
| SCHEMBL5285160 | 0.82 | HIF1A (0.49) | PTGS1PTGS2ADRB1ADRA1AMIF | |
| SCHEMBL5285167 | 0.82 | HIF1A (0.49) | PTGS1PTGS2ADRB1ADRA1AMIF | |
| SCHEMBL1653533 | 0.82 | PTGS1 (0.62) | PTGS1PTGS2MT-CO2KMT2AHPGD | |
| SCHEMBL29484096 | 0.82 | PTGS1 (0.62) | PTGS1PTGS2MT-CO2KMT2AHPGD | |
| SCHEMBL1492817 | 0.82 | PTGS1 (0.62) | PTGS1PTGS2MT-CO2KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117142955-A | Method for catalyzing carbonylation esterification reaction by cobalt promoted by molybdenum disulfide | 中国科学院兰州化学物理研究所 | 2023-12-01 | — | — | CN | claimed |
| CN-116730836-A | Method for catalyzing carbonylation esterification reaction by cobalt salt activated by synthesis gas | 中国科学院兰州化学物理研究所 | 2023-09-12 | — | — | CN | claimed |
| CN-117142955-A | Method for catalyzing carbonylation esterification reaction by cobalt promoted by molybdenum disulfide | 中国科学院兰州化学物理研究所 | 2023-12-01 | — | — | CN | disclosed |
| CN-116730836-A | Method for catalyzing carbonylation esterification reaction by cobalt salt activated by synthesis gas | 中国科学院兰州化学物理研究所 | 2023-09-12 | — | — | CN | disclosed |
| CN-110092709-B | Synthetic method of non-urethane intermediate 2-phenyl-1, 3-propylene glycol | 深圳市第二人民医院 | 2022-03-04 | — | — | CN | disclosed |
| US-20120316169-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2012-12-13 | — | — | US | disclosed |
| EP-2493846-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe S.p.A. (IT) | 2012-09-05 | — | — | EP | disclosed |
| CN-102656140-A | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them | DOMPE SPA | 2012-09-05 | — | — | CN | disclosed |
| WO-2011051375-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2011-05-05 | — | — | WO | disclosed |
| EP-2316820-A1 | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010138901-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS, DERIVATIVES THEREOF, AND RELATED METHODS OF USE | BIOGEN IDEC MA INC (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-1602642-A1 | IMINO ETHER DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-1585733-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1453795-A2 | ESTERS AND AMIDES AS PPAR-ALPHA AGONISTS | Dr. Reddy's Laboratories Ltd. (IN) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004063166-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED | 2003-12-11 | — | — | US | disclosed |
| WO-2003048116-A2 | ESTERS AND AMIDES AS PPAR-ALPHA AGONISTS ____________ | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-06-12 | — | — | WO | disclosed |
| US-4761420-A | CARDIOVASCULAR DISORDERS | LABORATOIRES SYNTEX S.A. (FR) | 1988-08-02 | — | — | US | disclosed |
| EP-0249245-A2 | Antihypertensive dihydropyridine derivatives | LABORATOIRES SYNTEX S.A. (FR) | 1987-12-16 | — | — | EP | disclosed |
| US-4117234-A | DERIVATIVES OF 2-(6-PHENYLHEX-3-ENYL)-CYCLOPENT-2-EN-1-OL | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316169-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BDKRB2, BDKRB1, CNR2 | PTGS1 79/4885PTGS2 66/4885MT-CO2 4144/4885 |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, PCSK9 | PTGS1 2630/4885PTGS2 3694/4885MT-CO2 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.